

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

COMP/M.5555 - NOVARTIS / EBEWE SPEZIAL-PHARMA HOLDING

SECTION 1.2

Description of the concentration

On 18 August 2009, the Commission received a notification of a concentration pursuant to Article 4 of Council Regulation EC No 139/2004 ("ECMR") by which Novartis AG, Basel/Switzerland (together with affiliates "Novartis Group") intends to acquire indirect sole control in the meaning of Article 3(1)(b) ECMR over EBEWE Spezial-Pharma Holding GmbH, Vienna/Austria (together with affiliates "EBEWE SP Group").

The business activities of the parties to the concentration are the following:

The Novartis Group is a pharmaceutical company active in the development, production and distribution of medical products, including prescription drugs, over-the-counter ("OTC") drugs, human vaccines, and animal health products.

EBEWE SP Group is active in the manufacture and distribution of specialty generic pharmaceutical products as well as in contract manufacturing of finished dose pharmaceuticals for other pharmaceutical companies.